Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4401
Acrivon Therapeutics
ACRV
$64.2M
| $66.4K | ﹤0.01% |
32,698
-5,393
| -14% | -$29K |
|
4402
Corbus Pharmaceuticals
CRBP
$166M
| $66.2K | ﹤0.01% |
12,470
-5,686
| -31% | -$50.2K |
|
|
FLNA
4403
Filana Therapeutics
FLNA
$48.8M
| $66.2K | ﹤0.01% |
44,130
-49,449
| -53% | -$125K |
|
4404
iShares iBonds Dec 2027 Term Corporate ETF
IBDS
$3.84B
| $66.1K | ﹤0.01% |
2,733
| – | – |
|
|
DOCT
4405
FT Vest US Equity Deep Buffer ETF October
DOCT
$385M
| $66K | ﹤0.01% |
1,721
-2,018
| -54% | -$79.6K |
|
4406
Telomir Pharmaceuticals
TELO
$83.2M
| $65.7K | ﹤0.01% |
20,339
-9,620
| -32% | -$42K |
|
4407
OP Bancorp
OPBK
$232M
| $65.6K | ﹤0.01% |
5,456
-4,590
| -46% | -$62.9K |
|
4408
FT Vest US Equity Buffer ETF August
FAUG
$1.19B
| $65.5K | ﹤0.01% |
1,441
-1,238
| -46% | -$57.9K |
|
4409
Gyre Therapeutics
GYRE
$641M
| $65.2K | ﹤0.01% |
8,451
-2,092
| -20% | -$22.9K |
|
4410
XBiotech
XBIT
$68M
| $65.2K | ﹤0.01% |
20,108
-9,896
| -33% | -$34.1K |
|
|
LNAI
4411
Lunai Bioworks
LNAI
$8.8M
| $65.1K | ﹤0.01% |
1,498
-750
| -33% | -$48K |
|
4412
FreightCar America
RAIL
$261M
| $64.9K | ﹤0.01% |
11,743
-9,702
| -45% | -$92.1K |
|
|
NOTE
4413
DELISTED
FiscalNote
NOTE
| $64.9K | ﹤0.01% |
6,693
-1,585
| -19% | -$23.8K |
|
4414
Suburban Propane Partners
SPH
$1.24B
| $64.8K | ﹤0.01% |
3,085
+116
| +4% | +$2.36K |
|
4415
Zegna
ZGN
$3.95B
| $64.7K | ﹤0.01% |
8,744
| – | – |
|
4416
Stem
STEM
$48.4M
| $64.7K | ﹤0.01% |
9,231
-2,406
| -21% | -$27.9K |
|
4417
Canadian Solar
CSIQ
$1.02B
| $64.3K | ﹤0.01% |
7,439
-3,417
| -31% | -$36K |
|
4418
Actinium Pharmaceuticals
ATNM
$26.3M
| $64.2K | ﹤0.01% |
39,871
-9,989
| -20% | -$12.7K |
|
4419
Cemex
CX
$17.1B
| $63.9K | ﹤0.01% |
11,384
+1,625
| +17% | +$9.83K |
|
|
SOHU
4420
Sohu.com
SOHU
$362M
| $63.8K | ﹤0.01% |
4,842
+3,696
| +323% | +$49.6K |
|
4421
PUT
Illumina
ILMN
$31B
| $63.5K | ﹤0.01% |
+800
| New | +$86.6K |
|
4422
Aemetis
AMTX
$106M
| $63.5K | ﹤0.01% |
36,466
-18,026
| -33% | -$38.5K |
|
4423
Global X Autonomous & Electric Vehicles ETF
DRIV
$377M
| $63.4K | ﹤0.01% |
3,000
| – | – |
|
4424
Noodles & Co
NDLS
$111M
| $63.4K | ﹤0.01% |
7,271
| – | – |
|
4425
Greenwich LifeSciences
GLSI
$198M
| $63.3K | ﹤0.01% |
6,633
-3,015
| -31% | -$36.6K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.